Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
Eledon Pharmaceuticals (NASDAQ: ELDN) reported its Q1 2022 results, showcasing a net loss of $9.9 million ($0.69 per share), up from a loss of $8.5 million ($0.57 per share) in Q1 2021. The increase in losses was primarily due to higher R&D expenses, which totaled $6.6 million, compared to $5.7 million last year. Significant developments include the completion of patient enrollment for the Phase 2a tegoprubart study in ALS, with topline data anticipated in June 2022, and the first patient dosed in the IgA Nephropathy trial, expanding the clinical footprint internationally.
- Anticipated topline data from the Phase 2a ALS study in June 2022.
- First patient dosed in the Phase 2a trial for IgA Nephropathy, with plans for broader international participation.
- Successful completion of a primate study for tegoprubart in preventing kidney allograft rejection.
- Net loss increased to $9.9 million in Q1 2022 from $8.5 million in Q1 2021.
- R&D expenses rose by $0.9 million, reflecting increased clinical development costs.
Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022
First patient dosed in Phase 2a trial evaluating tegoprubart in IgA Nephropathy with initial readout expected in late 2022
Successfully completed non-human primate study evaluating tegoprubart monotherapy in the prevention of kidney allograft rejection
Conference call today at 4:30 PM ET
IRVINE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today reported its first quarter 2022 operating and financial results.
“We are excited to approach the first of four distinct opportunities to highlight tegoprubart’s broad therapeutic potential this year, beginning with our upcoming ALS readout in June. Based on the growing body of evidence validating the CD40/CD40L pathway, we remain more encouraged than ever in the potential of tegoprubart as a best-in-class anti CD40L antibody,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “We continue to make progress across our clinical programs, highlighted by the recent Phase 2a trial initiation in IgAN, and are well positioned to announce meaningful clinical results throughout the remainder of the year.”
First Quarter 2022 and Recent Corporate Developments
- Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart in ALS and remain on track to deliver topline results in June 2022.
- Dosed the first patient in a Phase 2a clinical trial evaluating tegoprubart for the treatment of IgA Nephropathy. The ongoing trial currently has received regulatory clearances in Australia, New Zealand, Malaysia, and Spain, and the company plans to expand the study in up to seven additional countries in 2022.
- Successfully completed non-human primate study evaluating tegoprubart monotherapy in the prevention of kidney allograft rejection.
- Continued progress in two other clinical studies evaluating tegoprubart in kidney transplantation and islet cell transplantation with initial readouts anticipated in late 2022.
- Hosted first-ever Company R&D Day highlighting tegoprubart with four leading experts on ALS, renal transplantation, islet cell transplantation, and IgA Nephropathy (IgAN).
- Published meta-analysis comparing the efficacy of historical anti-CD40 and anti-CD40L approaches in the prevention of kidney transplant rejection in nonhuman primates.
Upcoming Anticipated Milestones
- 2Q 2022: topline data from Phase 2a trial of tegoprubart in ALS.
- 2H 2022: initial open label data from Phase 1b trial of tegoprubart in kidney transplantation.
- 2H 2022: initial open label data from Phase 2a trial of tegoprubart in IgAN.
- 2H 2022: initial open label data from Phase 2a trial of tegoprubart in islet cell transplantation.
Financial Results for the Three Months Ended March 31, 2022
The company reported a net loss of
- Research and development expenses were
$6.6 million for the three months ended March 31, 2022, compared to$5.7 million for the comparable period in 2021, an increase of$0.9 million . The increase in research and development spend primarily reflects an increase in clinical development costs and costs related to the production of clinical trial materials as we advance tegoprubart into global phase 1 and 2 clinical trials. - General and administrative expenses were
$3.2 million for the three months ended March 31, 2022, compared to$3.4 million for the comparable period in 2021, a decrease of$0.2 million . - The company had approximately
$76.7 million in cash and cash equivalents as of March 31, 2022, compared to$84.8 million in cash and cash equivalents as of December 31, 2021. The company believes that it has sufficient financial resources to fund operating activities into 2024.
Conference Call
Eledon will hold a conference call today, May 12, 2022, at 4:30 pm Eastern Time to discuss first quarter 2022 results. The dial-in numbers are 877-407-9039 for domestic callers and 201-689-8470 for international callers. The conference ID is 13729260. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.eledon.com. The webcast will be archived on the website following the completion of the call.
About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)
Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, the company’s capital resources and ability to finance planned clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sites, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company’s capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Source: Eledon Pharmaceuticals
ELEDON PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
(Unaudited)
| March 31, 2022 | December 31, 2021 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 76,677 | $ | 84,833 | ||||
| Prepaid expenses and other current assets | 2,648 | 3,513 | ||||||
| Total current assets | 79,325 | 88,346 | ||||||
| Operating lease asset, net | 675 | 768 | ||||||
| Goodwill | 48,648 | 48,648 | ||||||
| In-process research and development | 32,386 | 32,386 | ||||||
| Other assets | 344 | 400 | ||||||
| Total assets | $ | 161,378 | $ | 170,548 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,026 | $ | 1,813 | ||||
| Current operating lease liability | 328 | 369 | ||||||
| Accrued expenses and other liabilities | 1,604 | 2,219 | ||||||
| Total current liabilities | 2,958 | 4,401 | ||||||
| Deferred tax liability | 1,752 | 1,752 | ||||||
| Non-current operating lease liability | 350 | 400 | ||||||
| Total liabilities | 5,060 | 6,553 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Series X1 non-voting convertible preferred stock | — | — | ||||||
| Series X non-voting convertible preferred stock | — | — | ||||||
| Common stock | 14 | 14 | ||||||
| Additional paid-in capital | 281,067 | 278,880 | ||||||
| Accumulated deficit | (124,763 | ) | (114,899 | ) | ||||
| Total stockholders’ equity | 156,318 | 163,995 | ||||||
| Total liabilities and stockholders’ equity | $ | 161,378 | $ | 170,548 | ||||
ELEDON PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
(Unaudited)
| For the Three Months Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Operating expenses | ||||||||
| Research and development | $ | 6,635 | $ | 5,653 | ||||
| General and administrative | 3,224 | 3,352 | ||||||
| Total operating expenses | 9,859 | 9,005 | ||||||
| Loss from operations | (9,859 | ) | (9,005 | ) | ||||
| Other income/(expense), net | (5 | ) | 5 | |||||
| Loss before income tax benefit | (9,864 | ) | (9,000 | ) | ||||
| Income tax benefit | — | 501 | ||||||
| Net loss and comprehensive loss | $ | (9,864 | ) | $ | (8,499 | ) | ||
| Net loss per share, basic and diluted | $ | (0.69 | ) | $ | (0.57 | ) | ||
| Weighted-average common shares outstanding, basic and diluted | 14,330,693 | 14,831,049 | ||||||
FAQ
What were Eledon Pharmaceuticals' financial results for Q1 2022?
When is the topline data for the Phase 2a ALS study expected?
What significant trials is Eledon Pharmaceuticals currently conducting?
How much cash does Eledon Pharmaceuticals have?
